Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

Silverman, 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B., J Clin Oncol, 20, 2429, 10.1200/JCO.2002.04.117 Sudan, 2006, Treatment of acute myelogenous leukemia with outpatient azacitidine., Cancer, 107, 1839, 10.1002/cncr.22204 Silverman, 2006, Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B., J Clin Oncol, 24, 3895, 10.1200/JCO.2005.05.4346 Bhalla, 2005, Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies., J Clin Oncol, 23, 3971, 10.1200/JCO.2005.16.600 Goffin, 2002, DNA methyltransferase inhibitors: state of the art., Ann Oncol, 13, 1699, 10.1093/annonc/mdf314 Herman, 2003, Gene silencing in cancer in association with promoter hypermethylation., N Engl J Med, 349, 2042, 10.1056/NEJMra023075 Issa, 1997, DNA methylation changes in hematologic malignancies: biologic and clinical implications., Leukemia, 11, S7 Marks, 2001, Histone deacetylases and cancer: causes and therapies., Nat Rev Cancer, 1, 194, 10.1038/35106079 Yang, 2005, Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid., Leuk Res, 29, 739, 10.1016/j.leukres.2004.11.022 Garcia-Manero, 2005, Future directions for the use of hypomethylating agents., Semin Hematol, 42, S50, 10.1053/j.seminhematol.2005.05.004 Phiel, 2001, Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen., J Biol Chem, 276, 36734, 10.1074/jbc.M101287200 Johannessen, 2003, Valproate: past, present, and future., CNS Drug Rev, 9, 199, 10.1111/j.1527-3458.2003.tb00249.x Gottlicher, 2001, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells., EMBO J, 20, 6969, 10.1093/emboj/20.24.6969 Kuendgen, 2004, Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid., Blood, 104, 1266, 10.1182/blood-2003-12-4333 Kuendgen, 2006, The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia., Cancer, 106, 112, 10.1002/cncr.21552 Garcia-Manero, 2006, Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia., Blood, 108, 3271, 10.1182/blood-2006-03-009142 Appelbaum, 2000, NCCN practice guidelines for acute myelogenous leukemia., Oncology (Huntingt), 14, 53 Estey, 1999, Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome., Blood, 93, 2478, 10.1182/blood.V93.8.2478 Alimena, 1988, Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration., Blood, 72, 642, 10.1182/blood.V72.2.642.642 Di Croce, 2002, Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor., Science, 295, 1079, 10.1126/science.1065173 Yang, 2004, A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements., Nucleic Acids Res, 32, e38, 10.1093/nar/gnh032 Davis, 1994, Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy., Drugs, 47, 332, 10.2165/00003495-199447020-00008 Dreifuss, 1987, Valproic acid hepatic fatalities: a retrospective review., Neurology, 37, 379, 10.1212/WNL.37.3.379 Driever, 1999, Valproic acid for the treatment of pediatric malignant glioma., Klin Padiatr, 211, 323, 10.1055/s-2008-1043809 Garcia-Manero, 2005, Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome [abstract]., Blood, 106, 785a, 10.1182/blood.V106.11.4639.4639 Maslak, 2006, Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome., Leukemia, 20, 212, 10.1038/sj.leu.2404050 Gore, 2006, Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms., Cancer Res, 66, 6361, 10.1158/0008-5472.CAN-06-0080 Pilatrino, 2005, Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid., Cancer, 104, 101, 10.1002/cncr.21132 Raffoux, 2005, Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia., Haematologica, 90, 986 Garcia-Manero, 2006, Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) [abstract]., Blood, 108, 552a, 10.1182/blood.V108.11.1954.1954 Youssef, 2004, Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers., Cancer Res, 64, 2411, 10.1158/0008-5472.CAN-03-0164 Trus, 2005, The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells., Leukemia, 19, 1161, 10.1038/sj.leu.2403773 Cimino, 2006, Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia., Cancer Res, 66, 8903, 10.1158/0008-5472.CAN-05-2726 Cameron, 1999, Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer., Nat Genet, 21, 103, 10.1038/5047